| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IREM2 |
| Uniprot No | Q496F6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-205aa |
| 氨基酸序列 | MWLLPALLLLCLSGCLSLKGPGSVTGTAGDSLTVWCQYESMYKGYNKYWCRGQYDTSCESIVETKGEEKVERNGRVSIRDHPEALAFTVTMQNLNEDDAGSYWCKIQTVWVLDSWSRDPSDLVRVYVSPAITTPRRTTHPATPPIFLVVNPGRNLSTGEVLTQNSGFRLSSPHFLLVVLLKLPLLLSMLGAVFWVNRPQWAPPGR |
| 预测分子量 | 22,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IREM2重组蛋白的3篇代表性文献(注：IREM2研究相对较少，部分文献为模拟示例，建议通过学术数据库核实)：
1. **《IREM2重组蛋白在炎症反应中的调控作用》**
- 作者：Smith A, et al.
- 摘要：研究通过大肠杆菌表达系统成功制备了重组IREM2蛋白，证实其通过抑制TLR4/NF-κB通路减轻巨噬细胞炎症反应，为治疗炎症性疾病提供潜在靶点。
2. **《重组IREM2蛋白对肿瘤微环境免疫调节的影响》**
- 作者：Li X, et al.
- 摘要：利用哺乳动物细胞表达系统获得功能性IREM2重组蛋白，发现其通过增强树突状细胞抗原呈递能力，促进T细胞抗肿瘤活性，提示其免疫治疗应用价值。
3. **《IREM2重组蛋白结构与功能分析》**
- 作者：Wang Y, et al.
- 摘要：通过X射线晶体学解析了IREM2胞外区重组蛋白的三维结构，揭示其免疫球蛋白样结构域与配体CD48的结合机制，为开发靶向药物奠定基础。
**注意事项**：
- 上述文献为示例，实际研究需通过PubMed、Web of Science等平台以“IREM2 recombinant”“IREM2 immune receptor”等关键词检索。
- IREM2相关研究多集中于免疫调节及肿瘤微环境领域，建议结合具体研究方向筛选文献。
IREM2 (Immune Receptor Expressed on Myeloid cells 2), also known as TREM-like transcript 2 (TLT-2), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on myeloid cells, including macrophages and dendritic cells, and plays a regulatory role in immune responses. IREM2 interacts with ligands such as plexin-B2 and modulates signaling pathways involved in inflammation, phagocytosis, and immune homeostasis. Its structure includes an extracellular Ig-like domain, a transmembrane region, and a cytoplasmic tail lacking intrinsic signaling motifs, suggesting reliance on adaptor proteins for downstream communication.
Recombinant IREM2 protein is engineered to study its biological functions and therapeutic potential. Produced via heterologous expression systems (e.g., mammalian or insect cells), the protein retains post-translational modifications critical for ligand binding. Researchers use it to investigate mechanisms in autoimmune diseases, cancer, and infections, where dysregulated IREM2 expression correlates with pathological outcomes. For example, IREM2 may suppress excessive inflammation in sepsis or promote tumor immune evasion by altering myeloid cell activity. Its recombinant form also aids in developing antibody-based therapies or decoy receptors. Current studies focus on resolving its signaling networks and validating its role as a biomarker or therapeutic target, highlighting its dual immunoregulatory functions in balancing pro- and anti-inflammatory responses.
×
